HMC is attending CPhI 2018 in Madrid.

We are looking forward to see you there.

Your can meet us from Oct/09 – Oct/11 2018 in Madrid (Spain).

Heppe Medical Chitosan GmbH receives again certification according

EN ISO 13485:2012 + AC:2012 as well as EN ISO 9001:2008.

The certificates are available at the download section.

Abstract of the oral presentation at 13th EUCHIS 31st May-3rd June 2017.

More than 2000 publications and 20 published clinical trials within the last 12 month show that chitosan and chitosan derivatives are still attractive for the medical industry. As producer of well defined and pure chitosans and chitosan derivatives for pharmaceutical applications, with more than one hundred different specification for chitosans on the market and around 300 production batches per year HMC is always on the pulse of the market and in contact with regulatories and pharmaceutical companies worldwide.

Media attention for the HMC⁺ - Research. The highly pure Chitosan-products by HMC⁺ are in demand around the world. In addition to our production of highly pure chitosans and chitosan derivatives, we work together with our partners on new applications and other high-tech products.

Katja Richter, CEO of the company join the Family Day 2016 in Bonn. The FD16 (#FD16) is an invitation-only conference from the High-Tech Gründerfonds for networking of Germany’s best founders and CEOs from more than 266 HTGF portfolio companies with well known global players and the venture capital scene in Europe.

Heppe Medical Chitosan GmbH introduce a new version of the company brochure. Find compact information about our philosophy our quality and our products.